Business Context and Reporting Period
This Form 8-K reports on the reconvened 2025 Annual Meeting of Stockholders held by NanoViricides, Inc. on November 22, 2025. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol NNVC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A quorum was established with approximately 61% of outstanding voting capital stock present. Shareholders approved three proposals:
- Proposal 1 (Director Election): Re-election of Anil Diwan as a Class I Director.
- For: 9,757,652
- Against: 173,096
- Abstained: 48,971
- Proposal 2 (Executive Compensation): Advisory vote on named Executive Officers' compensation.
- For: 9,500,223
- Against: 420,374
- Abstained: 59,122
- Proposal 3 (Auditor Ratification): Ratification of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
- For: 14,594,257
- Against: 194,416
- Abstained: 60,051
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. It strictly documents the procedural outcomes of the shareholder meeting.
Investor Verification Checklist
- Verify the term expiration for the re-elected director (Anil Diwan) is set for the 2027 annual meeting.
- Confirm the appointment of EisnerAmper, LLP covers the fiscal year ending June 30, 2026.
- Review the Proxy Statement filed on October 7, 2025, for detailed descriptions of the proposals.
- Note that the meeting was reconvened, implying a prior meeting may have failed to achieve a quorum or required rescheduling.